{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:27Z","timestamp":1787701947994,"version":"build-2784847793"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with advanced-stage natural killer\/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the\u00a0China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male\/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had &amp;gt;1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86\/132, 65.2% vs. 54\/113, 47.8%, <jats:italic>P<\/jats:italic> = 0.006) and CR rates (60\/132, 45.5% vs. 27\/113, 23.9%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and OS (45.3 vs. 27.8%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in\u00a0the future.<\/jats:p>","DOI":"10.3389\/fonc.2020.583050","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T23:51:26Z","timestamp":1613865086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer\/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group"],"prefix":"10.3389","volume":"10","author":[{"given":"Weiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases","volume":"11","author":"Haverkos","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.44","article-title":"Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and Outcomes of Patients With Extranodal Natural Killer\/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3037","article-title":"Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2171-4","article-title":"Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer\/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2336-9","article-title":"Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy","volume":"94","author":"Bi","year":"2015","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0791-3","article-title":"Validation of Nomogram-Revised Risk Index and Comparison With Other Models for Extranodal Nasal-Type NK\/T-cell Lymphoma in the Modern Chemotherapy Era: Indication for Prognostication and Clinical Decision-Making","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.583050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T14:28:17Z","timestamp":1614176897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.583050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":21,"alternative-id":["10.3389\/fonc.2020.583050"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.583050","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"article-number":"583050"}}